ArticleFrontiers in immunology2026
Interleukin-6-to-lymphocyte ratio as a novel prognostic factor in patients with severe fever with thrombocytopenia syndrome: a discovery and validation study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease, characterized by cytokine storm and immune suppression. The interleukin-6-to-lymphocyte ratio (IL-6/LY) has demonstrated prognostic value in viral infections with dysregulated host immune responses. This study aimed to evaluate the prognostic value of IL-6/LY for early mortality in patients with SFTS. Methods: This multicenter cohort included 323 patients at Yantai Qishan Hospital (January 2022-December 2024) as the training cohort and 172 patients at Qingdao No. 6 People's Hospital (January 2023-October 2025) as the validation cohort. Univariable and multivariable logistic regression identified independent predictors of mortality. Prognostic performance was assessed using the area under the receiver operating characteristic (ROC) curve, and clinical benefit was evaluated by decision curve analysis (DCA). Survival was analyzed using the Kaplan-Meier method with the log-rank test. Results: A total of 495 patients were included in the study, with mortality rate of 21.21% (105/495). Multivariate logistic regression analysis identified DBV RNA level, age, and IL-6/LY as independent predictors of fatal outcome in SFTS. Compared with other predictors, IL-6/LY showed the strongest predictive performance for mortality in the training cohort (AUC = 0.839, 95% CI: 0.792-0.886; P < 0.001) and was externally validated with excellent discrimination (AUC = 0.812, 95% CI: 0.735-0.890; P < 0.001). Patients with elevated IL-6/LY levels (≥ 1.77) had a significantly lower survival probability than those with lower IL-6/LY (log-rank P < 0.001). DCA demonstrated great clinical benefit for IL-6/LY in both the training and external validation cohorts. Conclusion: IL-6/LY as a novel marker associated with immune dysregulation shows strong independent prognostic value for mortality in SFTS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.